SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

25 Jul 2018 07:00

RNS Number : 6057V
James Halstead PLC
25 July 2018
 

25 July 2018

 

 

Pre-Close Trading Statement

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2018.

 

We are pleased to report that sales for the year were ahead of the comparative year. This represents a creditable performance in still difficult trading conditions. It is particularly pleasing to report that our UK turnover is 3% ahead of the prior year in a market that seems to be quite robust despite the well reported spending cuts and high street retailer issues.

 

In the Chairman's interim statement, announced on 29 March 2018, it was noted that adverse price pressure on raw materials was holding back the benefits of export currency gains. This continued in the second half year but was ameliorated by increased sales. The Chairman, in that statement, noted that a German competitor had entered administration and at that time we decided to undertake our largest ever re-vamp of our homogenous flooring ranges with the launch of "Palettone."

 

Palettone is a premium homogenous sheet vinyl collection, launched in May 2018. It is the largest new product development by any manufacturer in this core product area in many years. It offers a collection of 50 colours optimised for our global market and is presented in a unique, innovative sample package with full customer support from specification to installation. The feedback we have received on the collection since launch has been exceptional.

 

The costs of development trials, sampling, marketing material and related costs have been around £2 million and the product has just been launched into the global market place. The timescale that our production and marketing staff worked to was ambitious and we are delighted with the successful launch.

 

In line with best practice, we shall expense these costs rather than amortise or construct an adjustment to "underlying" earnings.

 

Consequently we are pleased to anticipate, once again, reporting record turnover and expect profits for the year to 30 June 2018 will be in line with last year.

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

 

Mark Halstead, Chief Executive

 

Gordon Oliver, Finance Director

Telephone: 0161 767 2500

 

 

Nick Lyon - Hudson Sandler

Telephone: 020 7796 4133

 

 

Ben Thorne

Dominic Morley - Panmure Gordon

(Nominated advisor and broker)

 

Telephone: 020 7886 2500

 

Chris Hardie - Arden Partners

Telephone: 020 7614 5900

(Broker)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBZLFLVDFEBBX
Date   Source Headline
31st Mar 20237:00 amRNSInterim Results
2nd Feb 20237:00 amRNSTrading Update
1st Dec 20224:36 pmRNSResults of Annual General Meeting
1st Dec 20227:00 amRNSChairman’s Statement to the Annual General Meeting
14th Oct 20225:46 pmRNSPosting of Annual R&A and Notice of AGM
3rd Oct 20227:00 amRNSPreliminary Results
14th Sep 20221:01 pmRNSNotice of Preliminary Results
16th Aug 20223:59 pmRNSPDMR Exercise of Share Options
10th Aug 20224:00 pmRNSPDMR Grant of Share Options
1st Aug 20227:00 amRNSTrading Update
13th Jul 202211:24 amRNSBlock Listing Six Monthly Return
5th May 202210:48 amRNSTR-1: Notification of Major Holdings
31st Mar 20227:00 amRNSInterim Results
1st Feb 20227:00 amRNSTrading Update
17th Jan 202211:00 amRNSTotal Voting Rights and Application for Listing
13th Jan 20222:50 pmRNSApplication for Bonus Shares
7th Jan 20229:36 amRNSBlock Listing Six Monthly Return
7th Jan 20229:32 amRNSTotal Voting Rights
18th Nov 202111:13 amRNSResults of Annual General Meeting
18th Nov 20217:00 amRNSChairman’s Statement to the Annual General Meeting
15th Oct 20214:00 pmRNSPosting of Annual R&A and Notice of AGM
4th Oct 20217:00 amRNSPreliminary Results
20th Sep 20212:46 pmRNSNotice of Preliminary Results
4th Aug 20217:00 amRNSTrading Update
14th Jul 20215:00 pmRNSBlock Listing Six Monthly Return
25th Jun 20214:35 pmRNSPrice Monitoring Extension
22nd Jun 20214:00 pmRNSPDMR Exercise of Share Options
31st Mar 20217:00 amRNSInterim Results
1st Feb 20217:00 amRNSTrading Update
25th Jan 20217:00 amRNSBlock Listing Six Monthly Return
12th Nov 202011:00 amRNSResults of Annual General Meeting
12th Nov 20207:00 amRNSChairman's Statement to the Annual General Meeting
16th Oct 20204:00 pmRNSPosting of Annual Report and Notice of AGM
1st Oct 20207:00 amRNSPreliminary Results
24th Sep 20207:00 amRNSNotice of Preliminary Results
7th Sep 202010:12 amRNSTR-1 Notification of Major Holdings
14th Aug 20203:35 pmRNSTR1: Notification of Major Holdings
30th Jul 20207:00 amRNSPre-Close Trading Statement
28th Jul 20204:49 pmRNSBlock Listing Six Monthly Return
5th May 20207:00 amRNSAppointment of Joint Broker
31st Mar 20207:00 amRNSInterim Results
23rd Mar 20204:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:38 pmRNSPrice Monitoring Extension
23rd Mar 20201:00 pmRNSUpdate from the CEO
20th Mar 202012:08 pmRNSSecond Price Monitoring Extn
20th Mar 202012:03 pmRNSPrice Monitoring Extension
5th Feb 20204:59 pmRNSBlock listing Interim Review
5th Feb 20204:58 pmRNSTotal Voting Rights
30th Jan 20207:00 amRNSTrading Update
6th Dec 20194:35 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.